New York, NY (July 16, 2012) The Damon Runyon Cancer Research Foundation and the Sohn Conference Foundation have named three outstanding young scientists as the first-ever Damon Runyon-Sohn Pediatric Cancer Research Fellows, committing more than half a million dollars to help address a critical shortage of funding for pediatric cancer research.
The Sohn Conference Foundation, dedicated to curing pediatric cancers, announced in January that it was granting $1.5 million to the Damon Runyon Cancer Research Foundation, the leading charity supporting innovative young cancer researchers, to establish the award. It provides funding to basic scientists and clinicians who conduct research with the potential to significantly impact the prevention, diagnosis or treatment of one or more pediatric cancers.
July 2012 Damon Runyon-Sohn Fellows
Lara E. Davis, MD, with her sponsor Charles Keller, MD, at Oregon Health and Science University, Portland, Oregon, seeks to develop individualized, molecularly-targeted cancer therapy for osteosarcoma, a disease that accounts for only 2% of all pediatric cancers but is responsible for over 8% of all pediatric cancer deaths. She will establish primary cell cultures of osteosarcoma tumor samples from patients and identify genetic pathways in each individual sample that can be targeted with therapeutic agents. She will also use computer modeling to design drug combinations that may prevent the development of drug resistance. The goal of the proposed project is to improve osteosarcoma survival while decreasing therapy-related toxicity.
Angela J. Sievert, MD, with her sponsor John M. Maris, MD, at The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, is committed to developing more effective treatments for the many children diagnosed with brain tumors each year. Brain tumors are the leading cause of cancer-related death in children. Mutations in BRAF, an oncogene that can drive ca
|Contact: Yung S. Lie, Ph.D.|
Damon Runyon Cancer Research Foundation